UNG1-KO L428 cell line

Human Hodgkin lymphoma L428 UNG1 knock out using CRISPR-Cas9

Contributors

Inventor Institute
Bodil Merete Kavli Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology
Cat. #: 162355
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Blood cancer
Organism: Human
Tissue: Blood
Gender: Female
Model: Knock-Out
Morphology: Polymorphic
Growth properties: Suspension
Product description: Human Hodgkin lymphoma L428 cell line with abolished expression of UNG1
Gender: Female
CRISPR: Yes
Parental cell line: L428
Model description: UNG1 knock out using CRISPR-Cas9
disease: Hodgkin lymphoma
Format: Frozen
Shipping conditions: Dry ice
Biosafety level: 2
References:

Sarno et al., 2019. Nucleic Acids Res. 47(9):4569-4585, PMID: 30838409

Related Tools for Cell lines

Cat. # Tool Name
151425 TR146 Cell Line Key Info View Tool
151445 1-7HB2 Cell Line Key Info View Tool
151479 HCT 116 p300 KO [D10] Cell Line Key Info View Tool
151484 2fTGH Cell Line Key Info View Tool
151559 MEF UNG KO Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.